INDOCO Intraday Analysis...

INDOCO Share Price

Open 259.85 Change Price %
High 262.00 1 Day -4.85 -1.87
Low 252.20 1 Week -3.05 -1.18
Close 254.70 1 Month -29.20 -10.29
Volume 6461 1 Year -62.60 -19.73
52 Week High 362.00
52 Week Low 232.90
INDOCO Important Levels
Resistance 2 263.78
Resistance 1 260.04
Pivot 256.30
Support 1 249.36
Support 2 245.62
NSE INDIA Most Active Stocks
IFCI 27.25 16.45%
VISESHINFO 0.40 0.00%
SAIL 55.25 3.17%
SBIN 266.65 2.60%
ICICIBANK 268.45 2.17%
JINDALSTEL 74.20 1.50%
TANLA 59.75 19.98%
HCL-INSYS 61.30 1.07%
SUZLON 14.75 -1.01%
VEDL 245.45 1.03%
More..
NSE INDIA Top Gainers Stocks
VKSPL 0.15 50.00%
SFL 1032.00 41.37%
SFL 1032.00 41.37%
SFL 1032.00 41.37%
RASOYPR 0.20 33.33%
PARASPETRO 0.25 25.00%
VIMALOIL 43.20 20.00%
ATNINTER 0.30 20.00%
EUROTEXIND 33.60 20.00%
TANLA 59.75 19.98%
More..
NSE INDIA Top Losers Stocks
INDIANHUME 400.40 -51.39%
SPYL 1.75 -18.60%
SURANAIND 3.85 -15.38%
GLOBOFFS 94.85 -14.43%
SRGINFOTEC 0.30 -14.29%
KARMAENG 51.80 -9.44%
BANARBEADS 46.00 -8.46%
ZENITHBIR 0.65 -7.14%
AUSOMENT 33.05 -7.03%
ASIL 0.70 -6.67%
More..

Indoco Remedies Limited (NSE: INDOCO)

INDOCO Technical Analysis 5
As on 9th Dec 2016 INDOCO Share Price closed @ 254.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 291.51 & Strong Sell for SHORT-TERM with Stoploss of 294.71 we also expect STOCK to react on Following IMPORTANT LEVELS.
INDOCO Target for December
1st Target up-side 284.06
2nd Target up-side 302.44
3rd Target up-side 320.81
1st Target down-side 231.64
2nd Target down-side 213.26
3rd Target down-side 194.89
INDOCO Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 32.68 Sideways
MFI (14) MFI is Below 20 Over Sold
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Short Sell 279.32
10 Day Avg Volume Traded -74.78 % Less then 10 Day Average Volume
INDOCO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.indoco.com
INDOCO Address
INDOCO
Indoco House
166 CST Road
Mumbai, 400098
India
Phone: 91 22 2654 1851
Fax: 91 22 2652 0787
INDOCO Latest News
Indoco Remedies Q3 Net up 53 pc at Rs 21.6 crore   Economic Times   - 30th Jan 15
Indoco Remedies Ltd to consider Q3 results on Jan 30, 2015   Equity Bulls   - 17th Jan 15
Indoco Remedies Q2 net profit grows by 40 pc   Business Standard   - 21st Oct 14
Indoco Remedies Q1 profit up 118 pc; to file 10 ANDAs in FY15   Business Standard   - 30th Jul 14
Indoco Remedies' facilities in Goa receive FDA approval   VC Circle   - 22nd Jul 14
Indoco Remedies shares fall over US FDA 483   Business Standard   - 17th Jan 14
Indoco Remedies optimizing opportunities, says Nirmal Bang   Moneycontrol.com   - 31st Aug 13
Baring Buys And Reliance Capital Sells Shares Of Indoco Remedies   DealCurry   - 03rd Jul 13
Indoco Remedies launches new division, Indoco CND   pharmabiz.com   - 05th Apr 12
Indoco Remedies sees turnover doubling in two years   Daily News & Analysis   - 19th Aug 11
Interactive Technical Analysis Chart Indoco Remedies Limited ( INDOCO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Indoco Remedies Limited
INDOCO Business Profile
Based in Mumbai, Indoco Remedies was formed in Aug. 23, 1947. Indoco Remedies (INDOCO) makes formulations. The company also has a presence in contract manufacturing and research. It also trades some active pharma ingredients (APIs) manufactured by a group company. It has presence in the therapeutic segments including anti-infective, anti-cold preparation, opthalmic, anti-spasmodic, stomatology, anti-inflammatory and anti-fungal. The company`s shareholders are SPA Pharmaceuticals and Shanteri Investments. The company recently launched a new super specialty division with focus on diabetic and cardio-vascular segments. It has formed a 100% subsidiary, Indoco Holdings Netherlands BV, which would invest in Indoco UK and Indoco SA Pty a JV in South Africa. Indoco`s other subsidiary is Indoco Healthcare. In 2004-05, Indoco launched Methycal, a unique calcium supplement. It also acquired a brand Karvol Plus in the segment of decongestive inhalant from M/s Solvay Pharma (I) . Indoco availed of ECB loan of USD 2.50 million for financing the expansion of tablet facility of plant I at Verna. INDOCO exports branded formulations to several Asian and African countries. The current market capitalization stands at Rs 947.31 crore. Indoco Remedies has reported a standalone sales turnover of Rs 202.30 crore and a net profit of Rs 16.04 crore for the quarter ended September 2013. Other income for the quarter was Rs 0.42 crore. The company management includes Suresh G Kare - Chairman, Aditi Panandikar - Managing Director, Sundeep V Bambolkar - Joint Managing Director, D M Gavaskar - Director, Rajiv P Kakodkar - Director, Sharad P Upasani - Director, Anil M Naik - Director. The Registered office is at Indoco House, 166 CST Road, Kalina, Mumbai, Maharashtra - 400098.